The global blood culture test market is experiencing significant growth, driven by the rising prevalence of bloodstream infections, increasing cases of sepsis, growing concerns regarding antimicrobial resistance, and the expanding need for early and accurate infectious disease diagnosis. Blood culture testing plays a crucial role in identifying bacteria, fungi, and other microorganisms present in the bloodstream. These tests help healthcare professionals determine the cause of infections and support appropriate treatment decisions, particularly among critically ill patients.

Key Market Metrics and Industry Highlights

The blood culture test market is witnessing considerable transformation as healthcare providers increasingly prioritize rapid infection detection and effective patient management.

Important market figures include:

• Market Size (2025): USD 7.3 billion

• Market Size (2026): USD 8.2 billion

• Market Forecast (2033): USD 19.4 billion

• CAGR (2026–2033): 13.0%

• Largest Regional Market (2025): North America, with a revenue share of 40.5%.

• Fastest-Growing Region: Asia Pacific.

Download a free sample copy of the Blood Culture Test Market report to understand detailed coverage and inclusions in the final report

Rising Prevalence of Bloodstream Infections Driving Market Expansion

The increasing prevalence of bloodstream infections (BSIs) is one of the primary factors supporting the growth of the blood culture test market. Bloodstream infections can develop when harmful microorganisms enter the bloodstream, potentially resulting in severe complications, including sepsis and organ failure. Early identification of infection-causing pathogens is essential for initiating appropriate treatment and reducing the risk of adverse outcomes.

The growing number of hospitalizations, surgical procedures, intensive care admissions, and immunocompromised patients is increasing the demand for reliable diagnostic solutions. Blood culture tests help identify the microorganisms responsible for infections, enabling healthcare professionals to select appropriate antimicrobial treatments.

According to the World Health Organization, sepsis affects approximately 49 million people and causes 11 million deaths annually. This substantial disease burden highlights the importance of early diagnosis and effective infection management. Consequently, hospitals and diagnostic laboratories are increasingly incorporating advanced blood culture testing solutions into their diagnostic workflows.

Furthermore, growing awareness regarding antimicrobial stewardship is encouraging healthcare facilities to adopt diagnostic technologies that support targeted treatment rather than unnecessary antibiotic administration.

Technological Advancements Transforming Blood Culture Testing

Technological innovation is playing an important role in improving the accuracy, efficiency, and reliability of blood culture testing. Traditional diagnostic procedures often require extended incubation periods, which can delay pathogen identification and subsequent treatment decisions.

To address these challenges, manufacturers are developing automated blood culture systems, advanced microbial identification platforms, and molecular diagnostic technologies. These solutions help laboratories improve testing efficiency, streamline sample processing, and reduce manual intervention.

Automation is particularly important for high-volume diagnostic laboratories that process numerous patient samples daily. Automated instruments can continuously monitor culture bottles and detect microbial growth, supporting more efficient laboratory operations.

In addition, molecular diagnostic technologies are gaining attention because of their ability to identify microorganisms through genetic material. Their integration with conventional diagnostic workflows is expected to strengthen infection detection capabilities and support faster clinical decision-making.

Product Innovation and Growing Demand for Consumables

Based on product, the consumables segment dominated the blood culture test market, accounting for 59.1% of the total revenue share in 2025. Consumables include blood culture bottles, culture media, collection devices, and other materials required for sample collection and pathogen identification.

The increasing number of diagnostic procedures and rising incidence of infectious diseases are supporting demand for these products. Hospitals and clinical laboratories require a consistent supply of consumables to conduct routine and emergency blood culture testing.

Manufacturers are also focusing on developing improved blood collection devices and culture bottles to minimize contamination risks and improve diagnostic reliability. For instance, in February 2022, Kurin, Inc. announced the launch of its proprietary push-button needle system designed to improve blood collection safety.

Meanwhile, software and services are becoming increasingly important in automated diagnostic environments. Advanced software solutions help laboratories monitor test results, manage diagnostic workflows, and reduce errors associated with manual interpretation. 

Conventional and Automated Techniques Supporting Market Development

Based on technique, the conventional blood culture technique segment held the largest revenue share of 63.9% in 2025. Conventional techniques continue to be widely used across hospitals, pathology laboratories, and clinical diagnostic facilities because of their established procedures and broad clinical acceptance.

However, automated blood culture techniques are gaining momentum as healthcare providers increasingly seek efficient diagnostic solutions. Automated systems continuously monitor blood culture samples and help detect microbial growth with improved operational efficiency.

The growing adoption of automation is particularly beneficial for laboratories handling large testing volumes. These systems can reduce manual monitoring requirements and support standardized testing procedures.

Furthermore, increasing investments in laboratory infrastructure and the introduction of advanced diagnostic instruments are expected to encourage the adoption of automated blood culture techniques during the forecast period.

Culture-Based and Molecular Technologies Creating New Opportunities

Technology plays a significant role in determining the efficiency and accuracy of blood culture testing. Based on technology, culture-based technology dominated the market with a revenue share of 67.1% in 2025.

Culture-based testing remains widely adopted because it enables the growth and identification of microorganisms present in blood samples. Its established clinical applications and availability across healthcare facilities continue to support its market position.

At the same time, molecular technology is expected to register the highest CAGR during the forecast period. Molecular diagnostic solutions use advanced techniques to identify microbial genetic material and support faster pathogen detection.

The growing need for rapid diagnosis of bloodstream infections is encouraging manufacturers to invest in molecular diagnostic platforms and integrated testing solutions. These technologies can complement conventional culture methods by providing additional information that supports clinical decision-making.

Increasing Bacterial Infections Strengthening Application Demand

Based on application, the bacterial infections segment accounted for the largest market share of 69.6% in 2025. The growing prevalence of bacterial bloodstream infections and increasing concerns regarding antibiotic-resistant microorganisms are major factors contributing to this segment's dominance.

Blood culture testing helps healthcare professionals identify bacterial pathogens and determine appropriate treatment strategies. This is particularly important in intensive care units and emergency departments, where delays in diagnosing severe infections can negatively affect patient outcomes.

Meanwhile, fungal infection testing is also gaining importance due to the rising incidence of invasive fungal infections, particularly among immunocompromised individuals and hospitalized patients.

The increasing focus on infection prevention, early diagnosis, and antimicrobial resistance management is expected to support demand across both bacterial and fungal infection applications.

Go Deeper! Ask Prism AI

about the Global Blood Culture Test Market. Get instant answers to

questions related to market sizing, growth drivers & their impact, and more.

Hospitals and Diagnostic Laboratories Remain Major End Users

Hospitals and diagnostic laboratories represented the leading end-use segment, accounting for 70.2% of the global blood culture test market revenue in 2025.

These facilities perform a substantial volume of diagnostic procedures for patients experiencing suspected bloodstream infections, sepsis, and other infectious conditions. Their established laboratory infrastructure, trained medical professionals, and access to advanced diagnostic equipment contribute to the segment's market leadership.

Furthermore, increasing hospital admissions and the growing burden of healthcare-associated infections are encouraging healthcare facilities to strengthen their microbiology testing capabilities.

Diagnostic laboratories are also investing in automated instruments, advanced consumables, and integrated laboratory information systems to improve operational efficiency and testing capacity.

Regional Analysis: North America Leads While Asia Pacific Offers Growth Opportunities

North America dominated the global blood culture test market, accounting for 40.5% of total revenue in 2025. The region's leadership is supported by its well-established healthcare infrastructure, strong presence of diagnostic technology manufacturers, favorable reimbursement structures, and increasing awareness regarding early infection diagnosis.

The United States represents a major contributor to regional market revenue. Growing investments in clinical diagnostics, increasing prevalence of bloodstream infections, and the availability of advanced laboratory technologies are supporting market development.

Meanwhile, Asia Pacific is anticipated to register the highest CAGR from 2026 to 2033. Increasing hospital admissions, expanding healthcare infrastructure, and rising cases of urinary tract infections, bloodstream infections, and ventilator-associated pneumonia are contributing to regional growth.

Countries such as China, India, Japan, and South Korea are witnessing increasing investments in healthcare facilities and diagnostic laboratory infrastructure. The expansion of private healthcare providers and growing demand for advanced infectious disease testing are also expected to create opportunities for market participants.

Looking for more specific insights? Customize this report to suite your business needs

Competitive Landscape and Strategic Developments

The blood culture test market is characterized by continuous product innovation, research and development investments, strategic collaborations, and technological advancements. Leading companies are focusing on improving diagnostic accuracy, reducing testing time, and expanding their product portfolios to strengthen their market positions.

Some of the prominent companies operating in the market include:

• BD

• Terumo Corporation

• bioMérieux

• Bruker Corporation

• T2 Biosystems, Inc.

• Abbott Laboratories

• Luminex Corporation

• Siemens Healthineers AG

• F. Hoffmann-La Roche AG

• Danaher Corporation

Strategic collaborations are also supporting innovation in blood culture testing. For instance, in September 2023, BD collaborated with Navigate BioPharma Services, Inc. to accelerate the development and commercialization of new blood culture tests.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database